LENZ Therapeutics, Inc.
LENZHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeLENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. With a market capitalization of $161.8M, it sits in micro-cap territory. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults.
Market Cap
$161.8M
Beta
1.62
P/E (TTM)
—
P/E (Fwd)
-1.47
EPS (TTM)
$-3.79
EPS (Fwd)
$-3.51
ROE
-49.7%
ROA
-31.2%
Cash
$258.4M
Total Debt
$673,000
Free CF
-$48.8M
52W Change
-84.4%
Annual Financials
Cash vs Debt
Where LENZ stands vs its 150-day and 200-day moving averages
As of the July 7, 2026 close, LENZ finished 55.77% below its 150-day moving average ($12.66) and 69.42% below its 200-day moving average ($18.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LENZ overbought or oversold?
At the July 7, 2026 close, LENZ's RSI(14) was 23.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $258.4M in cash and $673K in debt, LENZ maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$48.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -49.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, LENZ tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LENZ's risk profile alongside its fundamentals and technical indicators provides a more complete picture.